BSX - Boston Scientific Corporation

NYSE - NYSE Delayed Price. Currency in USD
30.46
+0.19 (+0.63%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close30.27
Open30.20
Bid25.17 x 800
Ask0.00 x 36900
Day's Range30.18 - 30.46
52 Week Range24.54 - 30.84
Volume4,660,101
Avg. Volume7,108,327
Market Cap42.02B
Beta0.99
PE Ratio (TTM)400.79
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • BP, Boston Scientific, Madison Square Garden & Dillard's
    CNBC Videos7 days ago

    BP, Boston Scientific, Madison Square Garden & Dillard's

    The "Halftime Report" traders give their top stocks to watch for the second half

  • MARKETS: Stocks are selling off on the ISM miss, which also reveals problems in the factory sector
    Yahoo Finance Video23 days ago

    MARKETS: Stocks are selling off on the ISM miss, which also reveals problems in the factory sector

    Yahoo Finance's Jared Blikre joins Seana Smith from the New York Stock Exchange to discuss the latest market moves.

  • MARKETS: Boeing earnings smash estimates, but watch out for Caterpillar redux
    Yahoo Finance Video29 days ago

    MARKETS: Boeing earnings smash estimates, but watch out for Caterpillar redux

    Yahoo Finance's Alexis Christoforous and Jared Blikre break down the latest market action after Boeing reported first quarter earnings, beating estimates and raising full year guidance.

  • Zacks.com highlights: General Motors, Boston Scientific, Lam Research, NRG Energy and Celanese
    Zacks8 days ago

    Zacks.com highlights: General Motors, Boston Scientific, Lam Research, NRG Energy and Celanese

    Zacks.com highlights: General Motors, Boston Scientific, Lam Research, NRG Energy and Celanese

  • 5 Top ROE Stocks to Buy as U.S.-China Trade Concerns Subside
    InvestorPlace9 days ago

    5 Top ROE Stocks to Buy as U.S.-China Trade Concerns Subside

    The equity markets continued to breathe easy as the U.S.-China trade concerns abated with President Trump pledging support for the beleaguered Chinese telecom firm, ZTE, and the Qualcomm-NXP merger review process getting a roll-on with urgency from the top administration of China. A high ROE ensures that the company is reinvesting its cash at a high rate of return. ROE helps investors distinguish profit-generating companies from profit burners and is useful in determining the financial health of a company.

  • 5 Top ROE Stocks to Buy as U.S.-China Trade Concerns Subside
    Zacks9 days ago

    5 Top ROE Stocks to Buy as U.S.-China Trade Concerns Subside

    ROE helps investors distinguish profit-generating companies from profit burners and is useful in determining the financial health of a company.

  • ’60 Minutes’ Shines Harsh Light on Boston Scientific’s Gynecological Mesh
    InvestorPlace10 days ago

    ’60 Minutes’ Shines Harsh Light on Boston Scientific’s Gynecological Mesh

    This takes a look at the gynecological mesh, how it has affected women it was placed in, and the 48,000 lawsuits concerning it. The first bit of bad publicity for Boston Scientific is what has been happening to the gynecological mesh over time. The report then looks at how Boston Scientific makes the gynecological mesh.

  • The Wall Street Journal13 days ago

    [$$] Heart Device Procedure Is No Better Than Drug Therapy for Irregular Heartbeat: Study

    An increasingly common cardiovascular procedure using a device made by several medical technology companies was no better than drug therapy at preventing deaths, strokes and certain other complications, a new study found. The outcome of the trial raises questions about the procedure, known as catheter ablation, to treat patients with atrial fibrillation. Abbott Laboratories, Johnson & Johnson, Medtronic PLC and Boston Scientific Corp. make the device used in the procedure.

  • Will Boston Scientific Corporation (NYSE:BSX) Continue To Underperform Its Industry?
    Simply Wall St.15 days ago

    Will Boston Scientific Corporation (NYSE:BSX) Continue To Underperform Its Industry?

    Boston Scientific Corporation (NYSE:BSX) delivered a less impressive 1.59% ROE over the past year, compared to the 11.43% return generated by its industry. Though BSX’s recent performance is underwhelming, itRead More...

  • A Look at Abbott Laboratories’ Valuation Multiples
    Market Realist16 days ago

    A Look at Abbott Laboratories’ Valuation Multiples

    On May 3, Abbott Laboratories (ABT) was trading at a forward PE (price-to-earnings) ratio of 19.2x, while its PE ratio was 55.7x. This compares to the company’s forward PE and LTM (last-12-months) PE multiples of 20.1x and 57.6x, respectively, in April.

  • New Product Launches Drive ABT’s Medical Device Business
    Market Realist20 days ago

    New Product Launches Drive ABT’s Medical Device Business

    (Continued from Prior Part)ABT’s Medical Device business In 1Q18, Abbott Laboratories (ABT) registered sales of $7.4 billion, representing YoY (year-over-year) growth of ~16.7%. The company’s Medical Device segment registered strong growth and contributed ~37.0% to the company’s total sales, the highest of all four of its segments.  ABT’s Medical Device segment sales came in at ~$2.7 billion in 1Q18. On a reported basis, the segment’s sales growth was ~14.6% on a YoY basis. However, on an organic basis, the segment’s sales increased ~9.4%. ...

  • ABT’s Medical Devices Business: A Key Growth Driver
    Market Realist20 days ago

    ABT’s Medical Devices Business: A Key Growth Driver

    On April 18, Abbott Laboratories (ABT) released its 1Q18 earnings results. The company registered revenues of $7.4 billion, which represents YoY (year-over-year) growth of ~16.7%. These sales results exceeded analysts’ estimates. 

  • ABT’s Recent Stock Slump: What’s behind the Decline?
    Market Realist21 days ago

    ABT’s Recent Stock Slump: What’s behind the Decline?

    On May 2, Abbott Laboratories (ABT) ended trading at a closing price of $58.14 per share. Currently, the stock is trading lower than its 50-day moving average of $59.91 and near its 200-day moving average of $58.22.

  • Analysts’ Recent Recommendations and Target Price for ABT Stock
    Market Realist21 days ago

    Analysts’ Recent Recommendations and Target Price for ABT Stock

    Abbott Laboratories (ABT) reported its 1Q18 results on April 18. Let’s look at Wall Street analysts’ recommendations for ABT stock after its earnings release. On May 2, a Reuters survey noted that 20 brokerage firms were tracking ABT. Of these firms, 16 analysts recommended a “buy” or “strong buy.” The rest of the firms gave a “hold” rating on the stock. None of the firms gave a “sell” recommendation for Abbott Laboratories.

  • Thermo Fisher Scientific’s 1Q18 Sales Beat Estimates, Stock Up
    Market Realist28 days ago

    Thermo Fisher Scientific’s 1Q18 Sales Beat Estimates, Stock Up

    On April 25, Thermo Fisher Scientific (TMO) announced its earnings results for 1Q18, which ended on March 31. Its revenues grew ~23% to ~$5.9 billion YoY (year-over-year). The sales results came in ahead of analysts’ estimate of ~$5.6 billion.

  • Boston Scientific Raised Its 2018 Outlook
    Market Realist28 days ago

    Boston Scientific Raised Its 2018 Outlook

    On April 25, Boston Scientific announced its 1Q18 earnings results. Boston Scientific’s results exceeded analysts’ estimates and the company guidance. During the earnings release, Boston Scientific updated its outlook for fiscal 2018. The company expects to register fiscal 2018 sales of $9.75 billion–$9.9 billion. The EPS (earnings per share) in fiscal 2018 is expected to be $1.37–$1.41.

  • Boston Scientific’s 1Q18 Results: Key Highlights
    Market Realist28 days ago

    Boston Scientific’s 1Q18 Results: Key Highlights

    Boston Scientific: Strong 1Q18 Results, Higher 2018 OutlookBoston Scientific announced its 1Q18 results

  • Thomson Reuters StreetEvents28 days ago

    Edited Transcript of BSX earnings conference call or presentation 25-Apr-18 12:00pm GMT

    Q1 2018 Boston Scientific Corp Earnings Call

  • Boston Scientific Ducks 'Choppy' Earnings Season That Slammed Edwards
    Investor's Business Daily29 days ago

    Boston Scientific Ducks 'Choppy' Earnings Season That Slammed Edwards

    Boston Scientific rose Wednesday after quarterly sales and adjusted profit beat, but investors are still waiting for an update on its heart valves.

  • Reuters29 days ago

    Heart valve demand helps drive Boston Scientific's forecast

    Boston Scientific Corp raised its full-year forecast on Wednesday after reporting stronger-than-expected growth across its businesses, soothing fears that it was losing share in the lucrative market for heart valves. The company, which lags behind Medtronic Plc and Edwards Lifesciences Corp in the heart valves market, is pinning its hopes on its updated Lotus device, set for launch in 2019, following the withdrawal of an earlier version from Europe last year.

  • Boston Scientific (BSX) Beats on Q1 Earnings, Lifts '18 View
    Zacks29 days ago

    Boston Scientific (BSX) Beats on Q1 Earnings, Lifts '18 View

    Boston Scientific (BSX) registers steady growth across all business lines and geographies in Q1.

  • Should Boston Scientific Corporation’s (NYSE:BSX) Recent Earnings Decline Worry You?
    Simply Wall St.29 days ago

    Should Boston Scientific Corporation’s (NYSE:BSX) Recent Earnings Decline Worry You?

    For investors with a long-term horizon, examining earnings trend over time and against industry peers is more insightful than looking at an earnings announcement in one point in time. InvestorsRead More...

  • Associated Press29 days ago

    Boston Scientific: 1Q Earnings Snapshot

    Boston Scientific Corp. (BSX) on Wednesday reported first-quarter net income of $298 million. On a per-share basis, the Marlborough, Massachusetts-based company said it had net income of 21 cents. Earnings, ...

  • Reuters29 days ago

    Medical device maker Boston Scientific posts 10 pct rise in sales

    U.S. medical device maker Boston Scientific Corp reported a 10 percent rise in first-quarter net sales on Wednesday, helped by higher demand for its products, including pacemakers and heart valves. Net ...